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Studies of Irritable Bowel Syndrome (IBS) and other biopsy-
chosocial disorders show a great variety of approaches to
important clinical challenges. The papers in this special issue
shed light on new and interesting aspects of IBS.
IBS has a surprisingly uniform worldwide distribution,
from east to west and north to south, and aﬀects males and
females and all age groups [1, 2]. The prevalence rates vary
from 2% to 22% and the disorder is everywhere related to a
high degree of comorbidity (psychiatric distress, muscle-ske-
letal complaints, etc.), increased use of health care resources,
and environmental factors (early life events, familial factors,
infections, diet, social factors, etc.) [2, 3]. In this issue, the
s t u d yb yA .L´ opez-Colombo et al. “The epdimology of func-
tional gastrointestinal disorders in Mexico: a population-based
study” conﬁrmed this pattern in the ﬁrst population-based
study on functional gastrointestinal disorders in Mexico. IBS
had a prevalence rate of 16% and was associated with depres-
sion and increased use of health care resources.
A substantial proportion of patients with IBS report on-
set of their symptoms after acute gastroenteritis [4], and in a
recent meta-analysis it was demonstrated that the risk of de-
veloping IBS following infectious gastroenteritis was in-
creased sixfold [5]. Several risk factors for developing post-
infectious IBS have been demonstrated, related to the patho-
gen or the infection and genetic, clinical or environmental
factors [6]. However, the majority of the published studies so
far have included subjects living in the industrialized world,
and it is therefore not clear if the same relationship between
gastrointestinal(GI)infectionsandthedevelopmentoflong-
standing GI symptoms exists in the developing world. In
these countries the inhabitants are exposed to acute and
chronic GI infections to a larger extent, beginning already in
infancy. Therefore, the contribution of Morgan et al. “Irri-
table bowel syndrome and gastrointestinal parasite infection in
a developing nation environment” in this issue of Gastroen-
terology Research and Practice is a welcome contribution to
this research area. The authors included a large group of sub-
jects from a population-based sample in Nicaragua, and
studied one group of subjects with IBS and a randomly sel-
ected group without IBS. Parasite carriage in fecal samples,
which may serve as a surrogate for repeated exposures to ga-
strointestinal pathogens and infection, was investigated to
assess the association between repeated GI infections and
IBS. The main ﬁnding in this well-performed study was that
no diﬀerence in parasite carriage could be demonstrated
betweenIBScases(16.6%)andcontrols(15.4%),implicating
that the strong link between GI infections and development
of IBS seen in investigations from the industrialized coun-
triesmaynotbeapplicabletodevelopingcountries.However,
prospective studies in well-deﬁned cohorts are needed in
order to further assess this relationship, and to evaluate if
post-infectious IBS is a phenomenon speciﬁc to areas where
GI infections are not as common as in developing countries.
Itistemptingtospeculatethatthismayberelatedtodiﬀerent
immunological responses to GI infections based on the
background prevalence of infections consistent with hygiene
hypothesis, but this remains to be proven [7].
IBS and other functional gastrointestinal disorders are
characterized by a high rate of psychosocial comorbidity as
well as comorbidity with functional somatic syndromes such
as ﬁbromyalgia and chronic pelvic pain [8, 9]. These high
rates have been attributed to peripheral and central hyper-
sensitivity [10], which is modulated, in part, by stress and
psychological disorders such as anxiety, depression, and2 Gastroenterology Research and Practice
somatization [11]. Three papers in this issue relate to these
subjects. The paper by M.-J. Gerson and C. Gerson “The
importanceofrelationshipsinpatientswithirritablebowelsyn-
drome” reviews the eﬀect of a patient’s relationships (fami-
ly, friends, work) on the IBS illness experience. It concludes
that although this is a subject that has not received suﬃcient
attention in the medical literature and requires rigorous con-
ﬁrmation, relationships do have an impact on the IBS illness
experience and may even have an eﬀect on response to treat-
ment. Doctors should inquire whether family members and
intimate others are suﬃciently educated about IBS, and
whether they are supportive to the patient or whether there
are problems that can and should be addressed. A. S. Butt
et al. “Irritable bowel syndrome and psychiatric disorders in
Pakistan: a case control study” conducted a study in Pakistan
to estimate the frequencyand strength of association of com-
mon mental disorders (anxiety and depression) in patients
with IBS and controls. This is of particular interest because
thereisscantinformationinthemedicalliteratureonthesig-
niﬁcance of this association in Asian countries. The authors
foundthatthesedisordersaremorecommoninpatientswith
IBS in Pakistan, as in western countries, compared to other
chronic diseases including migraine and hypertension. L. B.
Olafsdottir et al. “Natural history of irritable bowelsyndrome
in women and dysmenorrhea: a 10-year follow-up study”f r o m
Iceland conducted a 10-year longitudinal study to assess as-
sociations between IBS and dysmenorrhea before and after
menopause.TheauthorsconcludedthatwomenwithIBSare
more likely to experience dysmenorrhea than women with-
outIBSandthatIBSsymptomseverityseemstoincreaseafter
menopause.Althoughthesepapersfocusondiﬀerentspeciﬁc
associations between IBS and common psychosocial and
comorbid conditions, taken together they add to the body
of information on these relationships with IBS and do so
from countries such as Pakistan and Iceland from which
there is relatively little available information.
Treatment of IBS includes a general therapeutic ap-
proach, lifestyle advice with dietary recommendations, psy-
chosocial support and pharmacotherapy, which all are eﬀec-
tive[3].However,sincemosttreatmentsbeneﬁtonlyamino-
rity, the treatment should be tailored on an individual basis.
IBS is a long-lasting, often life-long, disorder with an un-
dulating course and high placebo response rate. Despite the
chronicity of the disorder, most therapeutic trials are of ra-
ther short duration, commonly 3–6 months and show a high
rate of rapidly appearing relapses. S. Evangelista “Beneﬁts
from long term treatment in irritable bowel syndrome” gives
in this issue a good overview of the beneﬁts from long-term
treatment and takes into account the natural course of the
disorder, the placebo eﬀect, and the relapse rates related to
type and duration of the treatment. It is likely that pro-
longation of the treatment should be reserved for patients
withrecurrent symptoms, andthatcyclictreatmentmight be
appropriate for most patients due to the undulating natural
course of the disorder.
Despite years of research, today’s health care for patients
with IBS still merits improvement based on better under-
standing of the disorder [12]. The papers included in this
issue adds important new information to the IBS puzzle, but
we probably still have a long way to go and many studies to
perform before truly eﬀective treatments will be available.
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